WEB NEWS Research
Cryo-Cell International Inc (OTC:CCEL) ($7.08; $58.6M market cap) announced Q1 2024 results:
Sales of $7.8 million vs $7.8 million in the prior year, slightly missing analyst estimates of $7.9 million
Non-GAAP EPS of $0.07 vs non-GAAP EPS of $0.09 in the prior year ahead of analyst estimates for a loss of $0.02
“For the three months ended February 29, 2024, the Company recorded $503,000 in research, development and related engineering (“R&D”) expenses versus $79,000 for the three months ended February 28, 2023. The increase in R&D expenses as of the three months ended February 29, 2024 versus the same period in 2023 is due to the Clinical Study and Research Agreement the Company entered into with Duke to provide funding to complete the Duke IMPACT Study (as previously disclosed) and the expenses related to the development of a manufacturing laboratory related to the Duke License Agreement.”
The CCEL multibagger case still hinges on the company opening up stem cell infusion clinics to supplement its recurring revenue but no growth stem cell storage business.
CCEL is the world’s first private cord blood bank.
Research
Cryo-Cell International Inc (OTC:CCEL) ($6.41; $53.1M market cap) announced plans to explore strategic alternatives and spin-off of its newly formed subsidiary, Celle Corp.
“Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place.”
Recall in our February 29, 2024 earnings update for CCEL, the company had mentioned it was considering this possibility:
“To provide more financial flexibility to fund future projects, we intend to transfer the assets related to the Duke University Patent and Technology License Agreement and certain other assets into a newly formed, wholly-owned subsidiary. Once such transfer is completed, we will explore spinning off this subsidiary to the Company’s shareholders.”
Cryo-Cell International, Inc. is engaged in cryogenic cellular storage and the design and development of cellular storage devices. The company is the world’s first private cord blood bank.
Research
Cryo-Cell International Inc (OTC:CCEL) ($5.04; $41.7M market cap) a company that provides private and public cord blood banking solutions for stem cell treatments, announced Q3 2023 results:
Sales of $7.8 million vs $7.6 million in the prior year
Non-GAAP EPS of $0.08 vs non-GAAP EPS of $0.06 in the prior year
“We remain focused on driving forward the potential clinical use of cord blood and cord tissue cells to treat a variety of neurological indications, including cerebral palsy, autism, and hypoxic ischemic encephalopathy. We are currently funding the completion of a Phase 2 autism trial and expect to begin a Phase 3 CP trial in the first half of 2024. These clinical trials and the R&D investments associated with a commercial grade, stem cell laboratory are currently anticipated to be the major use of the Company’s cash flows over the next several years.”
Research
Cryo-Cell International Inc (OTC:CCEL) a company that provides private and public cord blood banking solutions for stem cell treatments, announced Q1 2023 results:
No commentary from management.
Research
Cryo-Cell International Inc (OTC:CCEL) ($3.82; $32.5M market cap), a company that provides private and public cord blood banking solutions for stem cell treatments, announced Q4 2022 results:
Sales of $8.2 million vs $7.7 million in the prior year
Non-GAAP EPS of $0.10 vs non-GAAP EPS of $0.08 in the prior year
There were no comments or outlook by management in the press release. From the 10-K:
“Due to equipment delivery delays, the Company is projecting to open the Cryo-Cell Institute for Cellular Therapies and begin infusing patients during fiscal 2024.”
It seems delays continue for the stem cell infusion clinics which was the major growth catalyst we covered in our research in August 2021.
Research
Cryo-Cell International Inc (NASDAQ:CCEL) ($5.20; $43.6M market cap), a company that provides private and public cord blood banking solutions for stem cell treatments announced a special cash dividend of $0.90, to be paid to shareholders on record as of the close of September 2, 2022.
“Cryo-Cell’s Chairman of the Board and Co-CEO, David Portnoy, stated “Cryo-Cell’s Board of Directors is pleased to reward its many long-time shareholders with this cash distribution while remaining committed to advancing cellular therapies using cord blood and cord tissue into clinical applications to help treat patients.”
Research
Cryo-Cell International Inc (OTC:CCEL), a company that provides private and public cord blood banking solutions for stem cell treatments announced its intent to advance its Cryo-Cell cellular therapy trials with Duke University to the next stage of clinical development.
“After several months of careful evaluation of the results from the early-stage clinical trials conducted by Duke University, Cryo-Cell believes that those results justify moving these cord blood and cord tissue cell therapy products to the next stage of clinical development.”
Research
Cryo-Cell International Inc (OTC:CCEL), a company that provides private and public cord blood banking solutions for stem cell treatments announced its third quarter 2021 results:
“We are proud to report another quarter of solid financial results even with the additional expenses related to our transformation into a vertically integrated, cellular therapy company.”
See our full “Reasons for Tracking” article here to see why we are bullish long term investors in CCEL.
